Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Irreversible Electroporation in Locally Advanced Pancreatic Cancer
NCT06378047Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2024
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in pancreatic cancer (PC), sponsored by Moffitt Cancer Center. Primary endpoint: Safety and Tolerability at 90 days. Started Apr 2024; status: completed.
02
Drugs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06378047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06378047.